KR20160105584A - COSMETIC COMPOSITIONS CONTAINING Rhododendron micranthum EXTRACT AND PREPARING METHOD OF THE SAME - Google Patents

Abstract

The cosmetic composition of the present invention and the method for producing the same provide a cosmetic composition having an anti-inflammatory and antioxidant activity and an anti-inflammatory and antioxidant functional cosmetic composition containing a tail azalea extract.

Description

TECHNICAL FIELD The present invention relates to an anti-inflammatory and antioxidant functional cosmetic composition containing a tail azalea extract and a method for preparing the same,

The present invention relates to a cosmetic composition and a method for producing the same, and more particularly, to a cosmetic composition containing a Rhododendron micranthum and having improved inflammation and antioxidative function, and a method for producing the same.

Inflammation is one of the defenses of the body against physical stimuli, chemical stimuli, bacterial infections, etc. It is one of the mechanisms to remove external substances and regenerate damaged areas. Once an inflammation-related stimulus is applied, vasoactive substances such as histamine, serotonine, bradykinin, prostaglandin, hydroxyeicosatetraenoic acid (HETE), leukotriene And the vascular permeability is increased to cause inflammation.

Monocytes are transformed into macrophages that are activated by bacterial infection and act as phagocytic cells. Macrophages induce inflammation by secretion of NO, prostaglandin E2, and proinflammatory cytokines, and regulatory cells important in both inflammation and immune response In order for macrophages to function in this way, they must undergo an activation process. LPS (lipopolysaccharide), one of the cell wall components of Gram-negative bacteria and well known as endotoxin, is the most well-known external factor involved in macrophage activation. Particularly, in monocytes and macrophages such as RAW 264.7 cells, proinflammatory cytokines such as TNF-α, IL-6 (interleukin-6) and IL-1β (interleukin- -inflammatory cytokine secreted by LPS (lipopolysaccharide) in the inflamed area. When LPS stimulates macrophages, nitric oxide (NO) is produced in the process of converting L-arginine into L-citrulline by an enzyme called iNOS (inducible nitric oxide synthase) Phagocytes produce NO.

In mammals, NO is synthesized by three kinds of NO synthase (NOS): nNOS (neuronal NOS), eNOS (endothelial NOS) and iNOS (inducible NOS). Among these, NO produced by nNOS and eNOS is produced for normal biological function, and the concentration in tissues is kept low to a certain level. However, the amount of NO produced by iNOS is excessively high, and it is harmful to living organisms such as pathological vasodilation, cytotoxicity and tissue damage. In addition, prostaglandin E2 (PGE2), an inflammatory factor, stimulates phospholipid, which is a constituent of cell membrane, stimulated by LPS, and arachidonic acid liberated by an enzyme called phospholipase A2 causes catalytic action of an enzyme called COXs (cyclooxygenase) And is induced to induce an inflammatory reaction. COX is classified as COX-1 and COX-2. COX-1 acts on normal biological functions such as platelet formation, gastric wall protection and maintenance of renal function in the body. COX-2 synthesizes PHE2 as an inflammatory mediator. PHE2 is known to be deeply involved in the development of cancer, such as promoting inflammation (pain, fever, etc.), immune response, and angiogenesis. Inhibition of iNOS is mostly due to its mechanism of action being linked to inhibitors of COXs. Therefore, iNOS inhibition materials that are relatively easy to search are discovered and developed as anti-inflammatory materials.

On the other hand, non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, have anti-inflammatory, antipyretic and analgesic effects. However, the long-term use of these drugs can sometimes lead to serious side effects. For example, secondary anemia due to gastrointestinal peptic ulcer bleeding, platelet function suppression, inhibition of induction of labor, side effects to the kidney, liver damage, hypersensitivity.

In order to overcome the side effects of these drugs, natural products such as plants are more preferable as a safer material. In this regard, researches are being actively carried out to find and use the anti-inflammatory materials in natural products.

The antioxidant function inhibits or slows down the oxidation reaction occurring in the body. Oxidation reaction in the body induces aging and cell transformation to generate cancer cells. Therefore, the antioxidant activity is a preventive measure to suppress the negative reaction in the body, and the public is also interested.

In the body, mitochondria within the cell, which is the main function of ATP production, generate free radicals, a byproduct of respiration, which is unstable, and is accompanied by other substances such as lipids, nucleic acids and proteins, It reacts to the enemy. Therefore, if we can prevent the generation of these free radicals, we can prevent the oxidation of the body, and indirectly, we can prevent aging and cancer. These antioxidant effects are difficult to experiment with free radicals occurring in the human body and use DPPH and ABTS radicals as biomarkers. The DPPH free radical scavenging activity assay is one of the methods for measuring the antioxidant activity of a sample. The DPPH free radical scavenging activity assay is a method for measuring the antioxidative activity of DPPH (1,1-diphenyl-2-picyl-hydrazyl) This method of decolorizing antioxidant activity is a widely used method because it can measure antioxidative activity in a relatively short time and has a high correlation with the antioxidant activity of plants.

The tail azalea is an evergreen broad-leaved shrub of the Rhododendron of the Ericaceae family, Rhododendron micranthum Turcz . And is a perennial plant distributed in Korea, China, and Manchuria. There are some attempts to cultivate plants with sunny footprints or water supply but with good water drainage, plants in rocky valleys and ornamental plants (native environment of the rare plant azalea, cuttings, seed breeding, , Journal of Forest Science Vol. 29, No. 2, pp. 165-172). No studies have been reported on the anti-inflammatory effect of this plant.

An object of the present invention is to provide an anti-inflammatory and antioxidant functional cosmetic composition containing a tail azalea extract having a skin free radical scavenging activity and inhibiting the production of NO by inhibiting the production of NO, And a manufacturing method thereof.

In order to accomplish the above object, the cosmetic composition according to an embodiment of the present invention comprises Rhododendron micranthum ) extracts.

The cosmetic composition may contain 0.001 to 20% by weight of the tail azalea extract.

The cosmetic composition has the function of anti-inflammation and antioxidation and can be used as a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutrition cream, , An essence, a nutritional essence, a pack, a soap, a cleansing foam, a cleansing lotion, a cleansing cream, a body lotion and a body cleanser.

The method of manufacturing cosmetics according to another embodiment of the present invention is characterized in that the tail azalea is extracted with an extraction solvent selected from the group consisting of alcohol having 1 to 5 carbon atoms, hexane, chloroform, alcohol, water, The process of producing azalea extract; And a process for producing a cosmetic product by adding an aqueous solution or an emulsion to the tail azalea extract.

The preparation of the tail azalea extract comprises a pretreatment step of preparing tail azalea dried powder by drying and pulverizing tail azalea; An extracting step of adding the extracting solvent at a weight of 3 to 20 times the dry weight of the dried rhododendron powder to the extract and conducting extraction at an extraction temperature of 20 to 120 ° C for an extraction period of 30 minutes to 10 days; And obtaining a tail azalea extract by removing solid matter from the tail azalea extract stock solution.

Hereinafter, the present invention will be described in more detail.

As a result of investigating the inflammation-inhibiting effect of various plant extracts, the inventors of the present invention found that the Rhododendron micranthum extract has an NO production inhibitory action and a DPPH free radical scavenging activity. When the extract is applied to cosmetics, it can be used as a functional cosmetic product, and thus the present invention has been accomplished.

The cosmetic composition according to one embodiment of the present invention comprises a Rhododendron micranthum extract.

The cosmetic composition contains a tail azalea extract and has antioxidant and anti-inflammatory functionality.

The tail azalea extract may be obtained by drying and crushing the leaves, stem, roots, flowers, fruits, plant outbreaks, or a mixture thereof of the tail azalea collected and pulverizing and extracting them using an extraction solvent.

The dried and crushed tail azalea may be a leaf, a stem, a root, a flower, or a mixture thereof of tail azalea, and the drying may be carried out in a known manner to such an extent that useful components in the collected tail azalea are not destroyed, For example, it can be carried out by a method of natural drying in the shade. In addition, it is preferable that the crushing is performed after crushing to such an extent that the useful components of the tail azalea can be sufficiently extracted in the subsequent extraction process. The drying and crushing steps may be carried out in reverse order or repeatedly as required.

The extraction may be carried out by, for example, hot water extraction, cold extraction, warming extraction, reflux cooling extraction, ultrasonic extraction, or the like, preferably by a cold extraction method.

The extraction is carried out using a solvent, and the solvent may be an alcohol having 1 to 5 carbon atoms, hexane, chloroform, hydrated alcohol, acetone, ethyl acetate ester, alcohol, water and mixtures thereof, preferably water, methanol, Ethanol, alcohol, and mixtures thereof.

The extraction is carried out at a temperature of from 20 to 100 DEG C, preferably from 20 to 70 DEG C for 30 minutes to 10 days, using a solvent having a weight of 3 to 20 times, preferably 3 to 10 times the dry weight of the tail azalea, , Preferably 1 hour to 1 day, may be applied. The extract may be continuously extracted from 1 to 5 times, preferably 2 to 3 times, including the dried and crushed product of the tail azalea, To obtain an extract. In addition, when scent extraction is carried out by cold precipitation, extraction is carried out at a temperature of 2 to 20 DEG C, preferably at a temperature of 4 to 15 DEG C for an extraction time of 30 minutes to 10 days, preferably 1 hour to 1 day Method may be applied, and the extract may be obtained by extracting the liquid phase one to five times, preferably two to three times continuously, including the drying and crushing of the tail azalea.

The liquid tail azalea extract can be separated from tail azaleas by a method such as vacuum filtration, and then concentrated or dried. For example, the liquid tail azalea extract may be a concentrate obtained by concentration under reduced pressure at 20 to 100 ° C, preferably 40 to 70 ° C by a vacuum rotary condenser, and the liquid tail azalea extract is dried to obtain a powdered tail azalea Extracts may also be obtained. The concentrated or powdered tail azalea extract can be used as needed in water, alcohol or a mixed solvent thereof. In addition, the liquid tail azalea extract, its concentrate or powder thereof may be an extract obtained by fractionation by nucleic acid or ethyl acetate or fractional stroke of the fraction.

The tail azalea extract is useful as a pharmaceutical composition for antiinflammatory activity by inhibiting the expression of iNOS which is an inflammatory mediator and inhibiting the expression of NO produced by the enzyme and containing components useful for the prevention and treatment of inflammation related diseases And preferably can be used as a pharmaceutical composition for the prevention or treatment of inflammatory diseases, and can be widely applied to inflammatory diseases.

The tail azalea extract may be contained in the cosmetic composition in an amount of 0.001 to 20.0% by weight. If the content of the tail azalea extract is less than 0.001% by weight, the effect of the present invention may be insufficient. If the content is more than 20.0% by weight, formulation may be difficult. In addition, the amount of the tail azalea extract may be in the range of 0.001 to 10.0% by weight, and may be included in the cosmetic composition in an amount of 0.001 to 5.0% by weight. . At this time, the weight of the tail azalea extract is based on the dried tail azalea extract which is made into the powder form by drying the tail azalea extract.

The cosmetic composition may contain, in addition to the above-mentioned tail azalea extracts, components used in external skin preparations such as cosmetics and medicines, such as other whitening agents, moisturizing agents, antioxidants, oily components, ultraviolet absorbers, surfactants, thickeners, Component, colorant, aqueous component, water, various skin nutrients, and the like can be appropriately blended as required.

Other examples include metal sequestrants such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate and gluconic acid, caffeine, tannin, verapamil, tranexamic acid and its derivatives, licorice extract, gabridine , Hydrothermal extract of firethorn fruit, various herbal medicines, drugs such as tocopherol acetate, glycyrrhizic acid and its derivatives or salts thereof, vitamin C, magnesium ascorbyl phosphate, ascorbic acid glucoside, arbutin, kojic acid, lucinol , Erragean, and chamomile, saccharides such as glucose, fructose, mannose, sucrose, trehalose, and the like can be appropriately blended.

In addition, the cosmetic composition may further comprise a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.

As the water-soluble vitamin, any of vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C and vitamin H may be used, And their salts (thiamine hydrochloride, sodium ascorbate, etc.) are also included in the water-soluble vitamins usable in the present invention. The water-soluble vitamin can be obtained by a conventional method such as a microorganism conversion method, a purification method from a culture of a microorganism, an enzymatic method, or a chemical synthesis method.

Examples of the above-mentioned useful vitamins include any of vitamin A, carotene, vitamin D2, vitamin D3 and vitamin E (d1-alpha tocopherol, d-alpha tocopherol and d-tocopherol) , And derivatives thereof such as palmitic acid ascorbin, stearic acid ascorbic acid, dipalmitic acid ascorbic acid, ac-1-tocopherol acetate, nicotinic acid dl-a tocopherol, DL- pantothenyl alcohol, D-pantonenyl alcohol, Etc.) are also included in the usable vitamins used in the present invention. Usability The vitamins can be obtained by a conventional method such as a microorganism conversion method, a purification method from a culture of a microorganism, an enzyme or a chemical synthesis method. The polymeric peptide may be any compound as long as it can be compounded in cosmetics, and examples thereof include collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, and keratin. The polymeric peptide can be obtained by a conventional method such as purification from a culture broth of a microorganism, an enzymatic method, or a chemical synthesis method, or it can be purified from natural products such as ducks such as pigs and cows and silk fiber of silkworms.

The polymeric polysaccharide may be any compound as long as it can be incorporated in cosmetics, and examples thereof include hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or a salt thereof (sodium salt, etc.). For example, chondroitin sulfate or a salt thereof can be usually purified from mammals or fish.

Sphingo lipids may be any as long as they can be incorporated into cosmetics, and preferable examples thereof include ceramides, phytosphingosine and sphingoglycolipids. Sphingoid lipids can be purified from ordinary mammals, fish, shellfish, yeast or plants by conventional methods or can be obtained by chemical synthesis.

The seaweed extract may be any of those which can be compounded in cosmetics. Preferably, the seaweed extract is selected from the group consisting of algae extract, red pepper extract, green algae extract, and carrageenan, arginic acid, arginic acid, Potassium alginate and the like are also included in the seaweed extract used in the present invention. Seaweed extract can be obtained from seaweed by a conventional method.

The cosmetic composition may be blended with other ingredients usually added to cosmetics, if necessary. Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation promoter, a cold agent, a restriction agent, and purified water.

Examples of the above-mentioned fat-soluble ingredients include ester-based fats, hydrocarbon-based fats, silicon-based fats, fluorine-based fats, animal fats and plant fats and the like. Examples of the ester-based oil include glyceryl tri-2-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isostearyl isostearate, But are not limited to, ethylbutyl, isobutylbutyl, butylbutyl, ethylbutylbutyl, isobutylbutyl, isobutylbutyl, isobutylisobutyl, isobutylisobutylisobutyl, isobutylisobutylisobutylisobutylisobutylisobutylisobutyl, Trimethylolpropane triisostearate, trimethylolpropane triisostearate, pentaerythritol tetra-2-ethylhexanoate, cetyl esters of caprylic acid, lauric acid Decyl, hexyl laurate, myristyl dicyl, myristyl myristate, myristine acid ethyl, stearyl stearate, decyl oleate, cetyl ricinoleate, lauryl Wherein the acid is selected from the group consisting of isostearyl isostearate, isostearyl isostearate, isostearyl isostearate, isostearyl isostearate, isostearyl isostearate, isostearyl isostearate, isostearyl isostearate, isostearyl palmitate, octyl stearate, isostearyl stearate, isodecyl oleate, octyldodecyl oleate, Propylene glycol dicaprylate, propylene glycol dicaprylylate, propylene glycol dicaprylylate, propylene glycol dicaprylate, propylene glycol dicaprylylate, propylene glycol dicaprylylate, propylene glycol dicaprylate, Glyceryl triacetate, glyceryl triisostearate, glyceryl triisostearate, octyldodecyl neopentanoate, octanoic acid, glyceryl triisostearate, glyceryl triisostearate, glyceryl triisostearate, glyceryl triisostearate, Octadecanoic acid octyldodecyl, isostearic acid isosetil, isostearic acid isostearyl, isoselic acid, Polyglycerin isostearic acid ester, triisocetyl citrate, triisocylic citrate, triisooctyl citrate, lauric acid lauryl, myristyl lactate, cetyl lactate, octyldecyl lactate, citric acid tri Ethylhexyl stearate, di-2-ethylhexyl succinate, diisobutyl adipic acid, diisopropyl sebacate, diisopropyl sebacate, diisopropyl sebacate, , Stearic acid cholesteryl, stearic acid cholesteryl, isostearic acid cholesteryl, hydroxystearic acid cholesteryl, oleic acid cholesteryl, isostearic acid cholesteryl, hydroxystearic acid cholesteryl, oleic acid cholesteryl Diethanolamine, diethanolamine, diethanolamine, diethanolamine, diethanolamine, diethanolamine, diethanolamine, diethanolamine, Stearyl hydroxystearate, isostearyl hydroxystearate, stearyl hydroxystearate, isostearyl hydroxystearate, stearyl 12-stearoyl hydroxystearate, ester of 12-stearoyl hydroxystearic acid, and the like. Examples of the hydrocarbonaceous oil include hydrocarbons such as squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, floating isoparaffin, polybutene, microcrystalline wax and vaseline. Examples of silicone based oils include polymethyl silicone, methyl phenyl silicone, methyl cyclopolysiloxane, octamethyl polysiloxane, decamethyl polysiloxane, dodecamethyl cyclosiloxane, dimethylsiloxane methyl cetyloxysiloxane copolymer, dimethylsiloxane methyl stearoxysiloxane copolymer, alkyl Modified silicone oils, and amino-modified silicone oils. Examples of the fluorine-based oil include perfluoropolyether and the like. Examples of the animal or plant oil include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, new flower oil, soybean oil, corn oil, rape oil, apricot kernel oil, palm kernel oil, palm oil, castor oil, sunflower oil, , Corn oil, palm oil, palm oil, cucumber nut oil, wheat germ oil, rice germ oil, shea butter, coltsfoot colostrum, macadamia nut oil, meadow home oil, egg yolk oil, woji, mayo, mink oil, orange raffia, jojoba oil, candelilla wax, Carnauba wax liquid lanolin, hardened castor oil, and the like.

Examples of the moisturizing agent include water-soluble low-molecular moisturizing agents, oil-soluble molecular moisturizing agents, water-soluble polymers, and oil-soluble polymers. Examples of the water-soluble low-molecular moisturizing agent include serine glutamine, sorbitol, mannitol, sodium pyrrolidone-carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol (Polymerization degree n = 2 or more), polyglycerin (polymerization degree n = 2 or more), lactic acid, lactic acid salt and the like. Examples of the lipid-soluble low-molecular moisturizing agent include cholesterol, cholesterol ester and the like. Examples of the water-soluble polymer include carboxyvinyl polymer, polyaspartic acid salt, tragacanth, xanthan gum, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, water-soluble chitin, chitosan, dextrin, . Examples of the oil-soluble polymer include polyvinylpyrrolidone eicosene copolymer, polyvinylpyrrolidone hexacene copolymer, nitrocellulose, dextrin fatty acid ester, and polymer silicone. Examples of the molient agent include long chain acyl glutamic acid cholesteryl ester, hydroxystearic acid cholesteryl, 12-hydroxystearic acid, stearic acid, rosin acid and lanolin fatty acid cholesteryl ester.

Examples of the surfactant include a nonionic surfactant, an anionic surfactant, and a cationic surfactant. Examples of the nonionic surfactant include self-emulsifying monostearic acid clicerine, propylene glycol fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan fatty acid ester, POE (polyoxyethylene) sorbitan fatty acid ester, POE sorbit fatty acid ester , POE glycerin fatty acid ester, POE alkyl ether, POE fatty acid ester, POE hydrogenated castor oil, POE castor oil, POE / POP (polyoxyethylene / polyoxypropylene) copolymer, POE / POP alkyl ether, polyether- We include acid alkanolamide, alkylamine oxides, hydrogenated soybean phospholipids, and the like. Examples of the anionic surfactant include fatty acid soap,? -Acylsulfonate, alkylsulfonate, alkylallylsulfonate, alkylnaphthalenesulfonate, alkylsulfate, POE alkylether sulfate, alkylamide sulfate, alkyl phosphate, POE alkyl phosphate, alkylamide Alkylsulfosuccinic acid salts, acylated hydrolyzed glycolipid salts, perfluoroalkyl phosphoric acid esters, and the like may be added to the composition of the present invention. . Examples of the cationic surfactant include alkyltrimethylammonium chloride, stearyltrimethylammonium chloride, stearyltrimethylammonium bromide, cetostearyltrimethylammonium chloride, phydistearyldimethylammonium chloride, stearyldimethylbenzylammonium chloride, behenyltrimethylammonium bromide, Benzalkonium chloride, diethylaminoethylamide stearate, dimethylaminopropylamide stearate, quaternary ammonium salts of lanolin derivatives, and the like. Examples of the amphoteric surfactant include carboxybetaine, amidebetaine, sulfobetaine, hydroxysulfobetaine, amidosulfobetaine, phosphobetaine, aminocarboxylate, imidazoline derivative, amideamine, etc. , And the like.

Examples of the organic and inorganic pigments include inorganic pigments such as silicic acid, silicic anhydride, magnesium silicate, talc, sericite, mica, kaolin, Bengala, clay, bentonite, titanium mica, titanium oxide, bismuth chloride, zirconium oxide, magnesium oxide, Inorganic pigments such as aluminum, calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, iron oxide, chromium oxide, chromium oxide, chromium oxide, But are not limited to, polyamide, polyester, polypropylene, polystyrene, polyurethane, vinyl resin, urea resin, phenol resin, fluorine resin, silicon resin, acrylic resin, melamine resin, epoxy resin, polycarbonate resin, Silk powder, cellulose, CI Pigment Yellow, CI Pigment Orange, and composite pigments of inorganic pigments and organic pigments thereof.

Examples of the organic powder include metal soaps such as calcium stearate; Metal salts of alkyl phosphates such as sodium zinc cetylate, zinc laurylate and calcium lauryl laurate; Acylamino acid polyvalent metal salts such as N-lauroyl- [beta] -alanine calcium, N-lauroyl- [beta] -alanine zinc and N-lauroylglycine calcium; Amidosulfonic acid multivalent metal salts such as N-lauroyl-taurine calcium and N-palmitoyl-taurine calcium; N-acyl basic amino acids such as N epsilon-lauroyl-L-lysine, N epsilon-palmitoylglycine, N alpha -pyattoylol nitin, N alpha -raurolyl arginine and N alpha -curable tallow fatty acid acyl arginine; N-acylpolypeptides such as N-lauroylglycylglycine; ? -amino fatty acids such as? -aminocaprylic acid,? -aminorauric acid and the like; Polyethylene, polypropylene, nylon, polymethylmethacrylate, polystyrene, divinylbenzene styrene copolymer, ethylene tetrafluoride, and the like.

Examples of the ultraviolet absorbers include para-aminobenzoic acid, aminopropyl p-aminobenzoate, octyl p-aminobenzoate, ethyleneglycol salicylate, phenyl salicylate, octyl salicylate, benzyl salicylate, butylphenyl salicylate, homomenthyl salicylate, benzyl cinnamate, Octyl methacrylate, dipyrromethoxy cinnamate mono 2-ethylhexane glyceryl, para-methoxy methacrylate isopropyl, diisopropyl / diisopropyl cinnamate ester mixture, urocanic acid, urocanic acid Ethyl, hydroxymethoxybenzophenone, hydroxymethoxybenzophenone sulfonic acid and dihydroxymethoxybenzophenone, sodium dihydroxymethoxybenzophenone disulfonate, dihydroxybenzophenone, tetrahydroxybenzophenone, 4- tert-butyl-4'-methoxydibenzoylmethane, 2,4,6-trianylino-p-1,3,5-triazine, and 2-benzotriazole.

Examples of the fungicide include hynokitiol, trichloroacetic acid, trichlorohydroxydiphenyl ether, chlorhexidine gluconate, phenoxyethanol, resorcin, isopropylmethyl phenol, azulene, salicylic acid, zinc pyrithione, benzalkonium chloride, No. 301, mononitro and eicol sodium, and undecylenic acid.

Examples of the antioxidant include butylhydroxyanisole, gallic acid propyl, and eicosorbic acid.

Examples of the pH adjuster include citric acid, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogenphosphate and the like.

Examples of the alcohol include higher alcohols such as cetyl alcohol.

The cosmetic composition may take the form of a solution, an emulsion, a viscous mixture or the like.

The ingredients contained in the cosmetic composition according to one embodiment of the present invention may contain, as an active ingredient, the ingredients commonly used in cosmetics in addition to the above extracts, for example, stabilizers, solubilizers, vitamins, And may contain conventional customary auxiliaries and carriers.

Cosmetics according to one embodiment of the present invention can be manufactured in any formulations conventionally produced in the art, and examples thereof include emulsions, creams, lotions, packs, foundations, lotions, essences, hair cosmetics and the like .

Specifically, the cosmetic according to an embodiment of the present invention may be used as a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, , Nutritional essences, packs, soaps, cleansing foams, cleansing creams, body lotions and body cleansers.

In the case of the paste, cream or gel of the formulation of the present invention, animal fiber, plant fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, a mixture of chlorofluorohydrocarbons, Propane / butane or dimethyl ether.

When the formulation of the present invention is a solution or an emulsion, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate benzyl alcohol, benzyl benzoate, propylene glycol, 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.

When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonium, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.

A method of manufacturing cosmetics according to another embodiment of the present invention includes extracting a tail azalea with an extraction solvent selected from the group consisting of alcohols having 1 to 5 carbon atoms, hexane, chloroform, alcohol, water and mixtures thereof, The process of preparing the extract; And a process for producing a cosmetic product by adding an aqueous solution or an emulsion to the tail azalea extract.

The preparation of the tail azalea extract comprises a pretreatment step of preparing tail azalea dried powder by drying and pulverizing tail azalea; An extracting step of adding the extracting solvent at a weight of 3 to 20 times the dry weight of the dried rhododendron powder to the extract and conducting extraction at an extraction temperature of 20 to 120 ° C for an extraction period of 30 minutes to 10 days; And obtaining a tail azalea extract by removing solid matter from the tail azalea extract stock solution. The contents of the tail azalea extract or the cosmetic composition are omitted from the description in the above.

The cosmetic composition of the present invention and a method for producing the same are natural anti-inflammatory and antioxidant extracts from plants and Rhododendron micronthum ) can be provided, and cosmetics having anti-inflammatory activity and antioxidative activity can be provided.

Fig. 1 shows the anti-inflammatory activity test results of Example 2 using the tail azalea extract prepared in Example 1 of the present invention.
FIG. 2 shows the anti-inflammatory activity test results of Example 2 using the tail azalea extract prepared in Example 1 of the present invention.
FIG. 3 shows the results of the antioxidant activity test of Example 3 using the tail azalea extract prepared in Example 1 of the present invention.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily carry out the present invention. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.

Example  One: Tail azalea ( Rhododendron micranthum ) Preparation of extract

Alcoholic extracts of Rhododendron sativus, tail azalea, were prepared by the following method.

60 g of the outpost of Rhododendron micranthum collected from Korea was immersed in methanol for one week at room temperature to obtain an extract obtained by cold precipitation. The extract was filtered and the solvent was distilled off to obtain 1.6 g of a methanol extract of tail azalea. This extract was dissolved in 0.5% DMSO at 1% by mass to prepare an extract solution of Example 1, and the extract solution was diluted and adjusted in concentration to apply to the following examples.

Example  2: Tail azalea  Anti-inflammatory activity test using extract

RAW 264.7 cultured cells were used for iNOS analysis.

RAW 264.7 cells were cultured in DMEM medium at 37 ° C in a CO ₂ incubator (95% air, 5% carbon dioxide). After culturing in a 96-well microplate for 24 hours, 2.5 μl of the sample solution diluted to 20, 4, 0.8 and 0.16 μg / ml, respectively, and 2 μl of LPS (1 μg / ml) The amount of NO production inhibited and iNOS activity was evaluated by measuring NO concentration and iNOS activity after 24 hours of incubation at a rate of 1 × 10 ⁵ RAW 264.7 cells per 500 μl of DMEM medium. Specifically, 50 μl of a Griess reagent was injected into each well, and the absorbance at 540 nm was measured. The results are shown in Table 1, FIG. 1 and FIG. 2. As a positive control, aspirin was applied in the same manner as above. Aspirin used inhibited iNOS activity by about 50% at a concentration of about 3.2 μg / mL and inhibited almost effectively at 100 μg / mL.

division Concentration (μg / ml) iNOS activity (%) Positive control group
(Aspirin) 3.2 50 Negative control group
(Negative control) - 100 Yangju repellent extract 20 6.65 4 21.30 0.8 41.42 0.16 59.53

Referring to Table 1, FIG. 1 and FIG. 2, it was confirmed that the tail azalea extract lowers NO concentration and iNOS activity in a concentration-dependent manner.

Example  3: Tail azalea  Antioxidant activity test using extract

The antioxidative activity of the tail azalea extract prepared in Example 1 was evaluated using the DPPH free radical scavenging activity test method.

Twenty microliters of TBEQ (positive control), methanol (negative control) and tail azalea extract solution (concentration of 2000, 1000, 500, 250, 125, and 65.5 μg / ml, respectively) prepared in Example 1 were added to each well of a 96- And reacted with 180 μl of 0.2 mM DPPH (1.1-diphenyl-2picyl-hydrazyl, Sigma chemical Co. USA) methanol solution. The microplate was wrapped with a foil to block the light, reacted at room temperature for 20 minutes, and the absorbance at 517 nm was measured and shown in FIG.

Referring to FIG. 3, it was confirmed that the tail azalea extract scavenges DPPH free radicals in a concentration-dependent manner, indicating that the tail azalea extract has an antioxidative activity like the quinone having the antioxidative function.

Hereinafter, examples of the external preparation for skin containing the anti-inflammatory and antioxidative functions of the present invention are prepared. The blended samples were prepared by the ingredients and contents shown in the following table, and the blending amounts were expressed in mass% or parts by mass.

Example  4: Tail azalea  Preparation of essence using extract

Using the tail azalea extract prepared in Example 1 above, the essence was prepared as follows. Specifically, in the following Table 2, an oil solution in which the components 1 to 13 are sequentially mixed is heated and dissolved at 75 DEG C, and the aqueous solution, in which the components 14 to 21 are sequentially mixed, is heated and dissolved at 75 DEG C, The mixture was stirred at 4000 rpm for 3 minutes to prepare a mixed solution. Thereafter, 22 was added to the mixed solution, and heated for 2 minutes. The mixed solution was mixed with the ingredients of 23 to 27 and emulsified to prepare an essence solution. The essence solution was further stirred at 50 DEG C at 4000 rpm for 2 minutes Followed by cooling to prepare the essence of Example 4.

No. Prescription Content (parts by mass) One Bees wax 0.3 2 Cetyltetheyl alcohol (Lanette O) 0.6 3 Emulsifier (Arlacel-165) 0.5 4 Surfactant (GMS-105) One 5 Surfactants (Arlacel-60) 0.5 6 Shea butter 0.3 7 Preservatives (Propyl paraben, P-P) 0.07 8 Mineral oil (Lily-70) 2 9 Serum (Estasan-3580) 1.5 10 White pigment (TIO) 1.2 11 Softener (Silicone 200F / 100CS) 0.4 12 Emulsifier (Myrj-52) One 13 Softener (Silicone 245) 5 14 Purified water 61.84 15 Metal ion sequestrants (EDTA-2Na (5%)) 0.4 16 Glycerine 8 17 Moisturizing agent (1, 3-butylene glycol) 7 18 Moisturizing agent (Aminocoat) One 19 Preservative (M-P) 0.2 20 Increasing agent (Keltrol-F (1%)) 2 21 Emulsion stabilizer (Carbopol 941 (2%)) 4 22 An acidity control agent (TEA (10%)) 0.8 23 Moisturizing agent (Na-Hyaluronic acid (1%)) One 24 Preservatives (Phenoxy Ethanol) 0.25 25 The tail azalea extract of Example 1 One 26 Yeast fermentation broth (Galactomyces) 0.02 27 Perfume 0.12

Example  5: Tail azalea  Production of lotion using extract

Using the tail azalea extract prepared in Example 1 above, a lotion was prepared as shown in Table 3 below. Specifically, the lotion according to one embodiment of the present invention is prepared by dissolving an oil solution in which the components 1 to 11 of Table 3 are successively mixed by heating at 75 ° C and successively mixing the components 12 to 18 at 75 ° C After heating and dissolution, the aqueous phase aqueous solution is mixed at 4000 rpm for 3 minutes. Then, the components of 19 to 24 were mixed and emulsified in such a solution, and the solution was mixed at 4000 rpm (2 minutes) at 50 DEG C and cooled to prepare the lotion of Example 5.

NO. Prescription Content (parts by mass) One Bees wax 0.3 2 Cetyltetheyl alcohol (Lanette O) 0.7 3 Surfactant (GMS-205) One 4 Stearic Acid 0.3 5 Surfactants (Arlacel-60) 0.6 6 Preservatives (P-P, Propyl paraben) 0.07 7 Mineral oil (Lily-70) 4 8 Serum (Estasan-3580) 3 9 Natural Squalane 4 10 Softener (Silicone 200F / 100CS) 0.5 11 Surfactant (Tween-60) 1.1 12 Purified water 65.6 13 Metal ion sequestrants (EDTA-2Na (5%)) 0.2 14 Glycerine 4 15 Moisturizing agent (1, 3-butylene glycol) 3 16 Preservative (Methyl paravene: MP) 0.2 17 Increasing agent (Keltrol-F (1%)) 5 18 Emulsion stabilizer (Carbopol 941 (2%)) 5 19 An acidity control agent (TEA (10%)) One 20 Moisturizing agent (Na-Hyaluronic acid (1%)) One 21 Preservatives (Phenoxy Ethanol) 0.25 22 The tail azalea extract of Example 1 One 23 Yeast fermentation broth (Galactomyces) 0.02 24 Perfume 0.16

Example  6: Tail azalea  Preparation of cream using extract

Using the tail azalea extract prepared in Example 1, the cream was prepared as shown in Table 4 below. Specifically, the cream according to an embodiment of the present invention comprises heating and dissolving an oily solution obtained by sequentially mixing the components 1 to 13 of Table 4 by heating at 75 ° C, mixing an aqueous solution containing components 14 to 21 in sequence Heat at 75 ℃ to dissolve. The aqueous phase solution was firstly emulsified at 4000 rpm for 3 minutes, 22 components were added to the solution for secondary emulsification at 4000 rpm, the components 23 to 27 were cooled to 50 캜, and the solution was subjected to tertiary emulsification , And cooling the finished solution at < RTI ID = 0.0 > 28 C < / RTI >

NO. Prescription Content (parts by mass) One Increasing agent (Cetanol 70) 1.5 2 Stearyl Alcohol 1.5 3 Surfactant (Arlacel-165) 0.7 4 Stearic acid 0.5 5 Maintaining (Myrj-52) One 6 Surfactants (Arlacel-60) One 7 Preservatives (P-P, Propyl paraben) 0.1 8 Natural Squalane 4 9 White pigment (TIO) 2 10 Skin Protector (S / W Petrolatum) One 11 Softener (ODM) 2 12 Softener (Silicone 200F / 100CS) 0.3 13 Softener (Silicone 245) 3 14 Purified water 56.83 15 Metal ion sequestrants (EDTA-2Na (5%)) 0.4 16 Glycerine 6 17 Moisturizing agent (1, 3-butylene glycol) 5 18 Moisturizing agent (Aminocoat) One 19 Preservative (M-P) 0.25 20 Increasing agent (Keltrol-F (1%)) 4 21 Emulsion stabilizer (Carbopol 941 (2%)) 5 22 An acidity control agent (TEA (10%)) 1.6 23 Moisturizing agent (Na-Hyaluronic acid (1%)) One 24 Preservatives (Phenoxy Ethano) l 0.1 25 The tail azalea extract of Example 1 One 26 Yeast fermentation broth (Galactomyces) 0.02 27 Perfume 0.2

All of the cosmetics obtained in Examples 4 to 6 above were subjected to an iNOS assay for evaluating anti-inflammatory activity and a DPPH free radical scavenging activity test for evaluating antioxidant activity, and they were confirmed to have anti-inflammatory and antioxidative effects, respectively.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, Of the right.

Claims (5)

Rhododendron micranthum extract. < / RTI > The method according to claim 1,
Wherein the cosmetic composition contains 0.001 to 20% by weight of the tail azalea extract. The method according to claim 1,
The cosmetic composition has the function of anti-inflammation and antioxidation and can be used as a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutrition cream, Wherein the cosmetic composition has any one of the formulations selected from the group consisting of an essence, a nutritional essence, a pack, a soap, a cleansing foam, a cleansing lotion, a cleansing cream, a body lotion and a body cleanser. The tail azalea is extracted with an extracting solvent selected from the group consisting of alcohols having 1 to 5 carbon atoms, hexane, chloroform, alcohol, water and mixtures thereof to prepare tailed azalea extract; And
And adding a water solution or an emulsion to the tail azalea extract to produce a cosmetic product. 5. The method according to claim 4, wherein the preparation of the tail azalea extract comprises:
A pretreatment step of drying and pulverizing the tail azalea to prepare tail azalea dry powder;
An extracting step of adding the extracting solvent at a weight of 3 to 20 times the dry weight of the dried rhododendron powder to the extract and conducting extraction at an extraction temperature of 20 to 120 ° C for an extraction period of 30 minutes to 10 days; And
And a step of obtaining a tail azalea extract by removing solid matter from the tail azalea extract stock solution.

Images